

Seznam zkratek

2-HG	D-2-hydroxyglutarát	MRI	Magnetic resonance imaging
ALK	Anaplastic lymphoma kinase	mTOR	Mammalian target of rapamycin
ATRX	Alpha-thalassemia/mental retardation, X-linked	MYB	Myeloblastosis oncogene
BRAF	V-Raf murine sarcoma viral oncogene homolog B	MYBL 1	Myb proto-oncogene like 1
CDK4/6	Cyclin-dependent kinase 4/6	NEC	Not elsewhere classified
CDKN2A/B	Cyclin-dependent kinase inhibitor 2A/B	NOS	Not otherwise specified
cIMPACT-Now	Consortium to inform molecular and practical approaches to CNS tumor taxonomy – not official WHO	NTRK	Neurotrophic tyrosine receptor kinase
CNS	Centrální nervový systém	OS	Overall survival
DNA	Deoxyribonukleová kyselina	PARP	Poly(ADP-ribózo)polymeráza
EANO	European association of neuro-oncology	PCV	Prokarbazin, lomustin a vinkristin
EGFR	Epidermal growth factor receptor	PFS	Progression-free survival
FGFR1	Fibroblast growth factor receptor 1	PR	Partial response
GBM	Glioblastoma multiforme	PTEN	Phosphatase and tensin homolog
G-CIMP	Glioma CpG island methylator phenotype	SD	Stable disease
H3F3A	H3 histone family member 3A	SHH	Sonic hedgehog
HR	Homologní rekombinace	TACC1/3	Transforming acidic coiled-coil-containing protein 1/3
IDH1/2	Izocitrát-dehydrogenáza 1/2	TERT	Telomerase reverse transcriptase
MAPK	Mitogen activated protein kinase	TP53	Tumor protein p53
MDM2	Murine double minute 2	WHO	The World health organization
MDM4	Murine double minute 4	WNT	Wingless/integrated
MGMT	O-6-Methylguanin DNA methyltransferáza	YAP1	Yes-associated protein 1
MHC	Major histocompatibility complex	ZFTA	Zinc finger translocation associated

LITERATURA

- Appay R, Dehais C, Maurage C-A, Alentorn A, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. *Neuro Oncol.* 2019;21:1519-28.
- Binabaj MM, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. *J Cell Physiol.* 2018;233:378-86.
- Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathol.* 2020;139:603-8.
- Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. *N Engl J Med.* 2016;374:1344-55.
- Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol.* 2013;31:337-43.
- Doroshov DB, Doroshov JH. Genomics and the History of Precision Oncology. *Surg Oncol Clin N Am.* 2020;29:35-49.
- Doz F, van Tilburg CM, Georger B, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. *Neuro Oncol.* 2022;24:997-1007.
- Ducray F, Sanson M, Chinot O, et al. KS02. 4. A Olaparib in Recurrent IDH-mutant High-Grade Glioma (OLAGLI). *Neuro Oncol.* 2021;23:iii4.
- Federici L, Capelle L, Annereau M, et al. 5-Azacitidine in patients with IDH1/2-mutant recurrent glioma. *Neuro Oncol.* 2020;22:1226-8.
- Gonzalez Castro LN, Wesseling P. The cIMPACT-NOW updates and their significance to current neuro-oncology practice. *Neurooncol Pract.* 2021;8:4-10.
- Kaley T, Touat M, Subbiah V, et al. BRAF Inhibition in BRAFV-600-Mutant Gliomas: Results From the VE-BASKET Study. *J Clin Oncol.* 2018;36:3477-84.
- Lassman AB, Sepúlveda-Sánchez JM, et al. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. *Clin Cancer Res.* 2022;28:2270-7.
- Loriot Y, Schuler MH, Iyer G, et al. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results. *JCO.* 2022;40:3007-3007.
- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* 2016;131:803-20.
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021;23:1231-51.
- Machida Y, Nakagawa M, Matsunaga H, et al. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model. *Mol Cancer Ther.* 2020;19:375-83.
- Mellinghoff IK, Ellingson BM, Touat M, et al. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. *J Clin Oncol.* 2020;38:3398-406.
- Mellinghoff IK, Penas-Prado M, Peters KB, et al. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. *Clin Cancer Res.* 2021;27:4491-9.
- Nabors LB, Ammirati M, Bierman PJ, et al. Central nervous system cancers. *J Natl Compr Canc Netw.* 2013;11:1114-51.
- Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell.* 2010;17:510-22.
- Ostrom QT, Patil N, Cioffi G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. *Neuro Oncol.* 2020;22:iv1-96.
- Platten M, Bunse L, Wick A, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. *Nature.* 2021;592:463-8.
- Polívka J, Polívka J jr, Potužník P. Jak léčit nádory mozku v současnosti. *Neurol. praxi.* 2021;22:206-11.
- Pusch S, Krausert S, Fischer V, et al. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. *Acta Neuropathol.* 2017;133:629-44.
- Rachdi A, Hernandez-Tost H, et al. Recent advances in the diagnosis and the treatment of primary CNS lymphoma. *Rev Neurol (Paris).* 2023;179:481-9.
- Reifenberger G, Wirsching H-G, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas – implications for classification and therapy. *Nat Rev Clin Oncol.* 2017;14:434-52.
- Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. *Acta Neuropathol.* 2014;128:551-9.
- Sepúlveda-Sánchez JM, Vaz MÁ, Balaña C, et al. Phase II trial of dacotinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. *Neuro Oncol.* 2017;19:1522-31.
- Smith HL, Wadhvani N, Horbinski C. Major Features of the 2021 WHO Classification of CNS Tumors. *Neurotherapeutics.* 2022;19:1691-704.
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med.* 2005;352:987-96.
- Sulkowski PL, Corso CD, Robinson ND, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. *Sci Transl Med.* 2017;9:eal2463.
- Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. *Cancer Chemother Pharmacol.* 2010;65:353-61.
- Torre M, Vasudevaraja V, Serrano J, et al. Molecular and clinicopathologic features of gliomas harboring NTRK fusions. *Acta Neuropathol Commun.* 2020;8:107.
- Turcan S, Fabius AWM, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. *Oncotarget.* 2013;4:1729-36.
- Unruh D, Zewde M, Buss A, et al. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. *Sci Rep.* 2019;9:8946.
- van den Bent MJ, Brandes AA, Rampling R, et al. Rando-